Start with acne, then reuse UniProt O43174 as the stable protein anchor across project notes and exports.
CHEMBL5141 Target Snapshot
Cytochrome P450 26A1 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O43174. Start with acne, then reuse UniProt O43174 as the stable protein anchor across project notes and exports.
Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acne because it currently carries clinical signal support. Linked drugs include TALAROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCytochrome P450 26A1
Review this target as Cytochrome P450 26A1, mapped to UniProt O43174. Sequence length is 497 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytochrome P450 26A1 as ChEMBL target CHEMBL5141, mapped to UniProt O43174. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cytochrome P450 26A1 is the right protein anchor across sources, using UniProt O43174 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acne is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cytochrome P450 26A1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O43174 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cytochrome P450 26A1 |
| UniProt Accession | O43174 |
| Component Type | Protein |
| Sequence Length | 497 aa |
Cytochrome P450 26A1
How to read this target
Review this target as Cytochrome P450 26A1, mapped to UniProt O43174. Sequence length is 497 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with acne because it currently carries clinical signal support. Linked drugs include TALAROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1831092 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL1831083 | 9.46 | IC50 | 0.35 | Preclinical |
| CHEMBL208443 | 8.89 | IC50 | 1.3 | Preclinical |
| CHEMBL205862 | 8.85 | IC50 | 1.4 | Preclinical |
| CHEMBL207304 | 8.8 | IC50 | 1.6 | Preclinical |
| CHEMBL57765 | 8.62 | IC50 | 2.4 | Preclinical |
| CHEMBL1766005 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL1766007 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL207486 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL368448 | 8.48 | IC50 | 3.3 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 28 assays, 187 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 16 | 89 | 5.7 |
| single protein format | 8 | 62 | 6.8 |
| microsome format | 4 | 36 | 7.4 |
Functional — 6 assays, 29 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 5 | 25 | 7.5 |
| microsome format | 1 | 4 | 7.3 |
ADME — 1 assays, 22 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 22 | 4.9 |